Scrideli Carlos Alberto, Queiroz Rosane Gomes de Paula, Bernardes José Eduardo, Valera Elvis Terci, Tone Luiz Gonzaga
Department of Pediatrics, Ribeirão Preto Medicine School, São Paulo University, Ribeirão Preto, Brazil.
Med Pediatr Oncol. 2003 Jul;41(1):10-6. doi: 10.1002/mpo.10154.
The initial response to induction therapy is currently considered one of the most important prognostic factors in acute lymphoblastic leukemias (ALL). A series of methods for the detection of submicroscopic levels of residual disease in patients with ALL mainly based on PCR and immunophenotyping has been developed, demonstrating that the presence of high levels of residual disease at the end of induction therapy is an important, independent prognostic factor. We determined the usefulness of PCR detection of minimal residual disease using consensus primers as a non-remission criterion.
Bone marrow samples obtained from 49 children with ALL were analyzed at diagnosis and at the end of induction therapy for the detection of clonal IgH, TCRdelta, and TCRgamma rearrangements by PCR. The results were compared with those obtained by standard morphologic analysis and risk group classification.
Patients who had clonality detected at the end of induction showed a significantly higher recurrence rate and lower event-free survival than those without detected clonality (24.9% vs. 89.7%) (P < 0.0001). Multivariate analysis revealed that detection of clonality at the end of induction was the most important, independent prognostic factor when associated with age, number of white blood cells, and immunophenotyping.
PCR detection of clonality using consensus primers is a relatively simple technique that is able to identify patients with a high chance of recurrence, and shows a higher sensitivity and a better prognostic value than standard morphologic analysis and risk group classification, defining a new remission criterion. However, further multicentric prospective studies using this technique employing a larger number of cases are necessary to confirm these findings.
诱导治疗的初始反应目前被认为是急性淋巴细胞白血病(ALL)最重要的预后因素之一。已经开发出一系列主要基于聚合酶链反应(PCR)和免疫表型分析来检测ALL患者亚微观水平残留疾病的方法,结果表明诱导治疗结束时高水平残留疾病的存在是一个重要的独立预后因素。我们确定了使用共有引物通过PCR检测微小残留疾病作为非缓解标准的实用性。
对49例ALL患儿在诊断时和诱导治疗结束时采集的骨髓样本进行分析,通过PCR检测克隆性免疫球蛋白重链(IgH)、T细胞受体δ链(TCRδ)和T细胞受体γ链(TCRγ)重排。将结果与标准形态学分析和风险组分类所获得的结果进行比较。
诱导治疗结束时检测到克隆性的患者与未检测到克隆性的患者相比,复发率显著更高,无事件生存率更低(24.9%对89.7%)(P<0.0001)。多变量分析显示,诱导治疗结束时克隆性的检测与年龄、白细胞数量和免疫表型分析相关时,是最重要的独立预后因素。
使用共有引物通过PCR检测克隆性是一种相对简单的技术,能够识别复发可能性高的患者,并且比标准形态学分析和风险组分类具有更高的敏感性和更好的预后价值,从而定义了一个新的缓解标准。然而,需要进一步开展多中心前瞻性研究,使用该技术纳入更多病例以证实这些发现。